Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?

Area of Science:

• Neurology
• Immunology
• Neuroimmunology

Background:

• Neuromyelitis optica (NMO) and NMO spectrum disorders (NMOSD) are inflammatory demyelinating diseases of the central nervous system.
• Case reports suggest interferon beta (IFN-β) treatment may worsen NMOSD.
• Accurate diagnosis is critical to distinguish NMOSD from multiple sclerosis (MS).

Purpose of the Study:

• To evaluate the efficacy and safety of interferon beta (IFN-β) in patients with NMOSD.
• To determine if IFN-β treatment exacerbates NMOSD.
• To assess the impact of IFN-β on relapse rates and disability progression in NMOSD.

Main Methods:

• Retrospective review of 40 NMOSD patients treated with IFN-β for over 6 months.
• Analysis of disease duration exceeding 1 year before IFN-β initiation.
• Evaluation of annualized relapse rates (ARR) and Expanded Disability Status Scale (EDSS) scores pre- and post-IFN-β treatment.

Main Results:

• 95% of patients showed ineffective or exacerbated responses to IFN-β.
• Mean ARR significantly increased post-IFN-β (p = 0.002).
• 50% of patients experienced ARR increase >50% with IFN-β; mean EDSS score significantly worsened (p < 0.001).

Conclusions:

• IFN-β is ineffective for preventing relapses in NMOSD.
• IFN-β treatment may significantly increase relapse frequency in NMOSD patients.
• Emphasizes need for careful NMOSD diagnosis and judicious treatment selection, especially for high-risk individuals.